Production of Igy Polyclonal Antibody Against Diphtheria Toxin and Evaluation of Its Neutralization Effect by Vero Cell Assay Publisher Pubmed



Rezaeifard M^{1, 2} ; Solhi R^{1, 2} ; Mohammadi M³ ; Abbasi E⁴ ; Aminian M^{1, 5} Show Affiliations
Source: BMC Biotechnology Published:2021

Abstract

Background: Diphtheria is a bacterial disease which is caused by Corynebacterium diphtheriae. The symptoms are due to the diphtheria toxin produced by the bacteria. Antibiotic therapy and the use of diphtheria antitoxin is a recommended strategy to control diphtheria. Although mammalian antibodies are used to treat patients, IgY antibody has advantages over mammalian ones, including cost-effectiveness and production through non-invasive means. Moreover, in contrast to mammalian antibodies, IgY does not bind to the rheumatoid factor and does not activate the complement system. The objective of this study was to evaluate the in vitro neutralizing effect of IgY against diphtheria toxin. Results: Anti-DT IgY was produced by immunization of the laying white leghorn chickens. Indirect enzyme-linked immunosorbent assay revealed successful immunization of the animals, and the IgY was purified with a purity of 93% via polyethylene glycol precipitation method. The neutralizing activity of the purified IgY was evaluated by Vero cell viability assay. This assay confirmed that 1.95 μg (8.6 μg/ml of culture medium) of anti-DT IgY would neutralize 10 fold of cytotoxic dose 99% of DT, which was 0.3 ng (1.33 ng/ml of culture medium). Conclusion: This anti-DT IgY may be applicable for diphtheria treatment and quality controls in vaccine production. © 2021, The Author(s).